Cellivery Signs Clinical Advisory Contract for Severe Sepsis Treatment New Drug iCP-NI with Tertiary General Hospitals
[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 21st that it has signed a clinical advisory contract with a tertiary hospital located in Seoul.
A company official stated, "With this clinical advisory contract with the tertiary hospital in Seoul, our strategy is to shorten the timeline for entering clinical trials of the severe sepsis treatment drug iCP-NI to the shortest possible period," adding, "the iCP-NI under development is a cell-permeable peptide sepsis drug that can block the 'cytokine storm' caused by excessive activation of the body's self-defence system due to bacterial, viral infections, or trauma such as traffic accidents or surgical operations, thereby suppressing systemic inflammatory responses."
Cellivery's iCP-NI is a novel drug that fundamentally suppresses sepsis by inhibiting the secretion of inflammatory cell signals called cytokines. The company also explained that in an acute severe hepatitis animal model conducted internally, a single administration of iCP-NI showed a 100% survival rate compared to 100% mortality in the control group.
Sepsis is a disease with a mortality rate close to 30%, characterized by symptoms such as multiple organ failure. Although various treatments are currently used for sepsis, the mortality rate remains high. Considering the lack of existing treatments for sepsis, the company expects that if the clinical trials of iCP-NI succeed, it will become a groundbreaking drug that can be immediately used in medical settings including emergency rooms.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "One Comment Could Lead to a Report": 86% of Elementary Teachers Feel Anxious; Half Consider Resignation or Career Change
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
A company official explained, "Currently, iCP-NI is being mass-produced as clinical samples at a specialized contract manufacturing organization (GMP CMO) that meets Good Manufacturing Practice (GMP) standards to enter clinical trials," adding, "Through this clinical advisory contract with the tertiary hospital in Seoul, we can expect faster clinical entry, as well as add a strategic pipeline for licensing out (L/O) during non-clinical and early clinical stages."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
